Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

Marinus Pharmaceuticals (Nasdaq: MRNS) announced their participation in SVB Leerink’s 2nd Annual CNS Forum on June 23, 2020, at 3:20 PM ET.

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced their participation in SVB Leerink’s 2nd Annual CNS Forum on June 23, 2020, at 3:20 PM ET. The presentation, titled "A Pipeline Update," will feature CEO Scott Braunstein and CMO Joe Hulihan discussing the company's innovative therapeutics for rare seizure disorders, particularly focusing on Ganaxolone. This drug acts on GABAA receptors and is being developed in various forms to enhance treatment for both adult and pediatric patients. Marinus is initiating multiple clinical trials, including a Phase 3 trial for children with CDKL5 deficiency.

Argus Session date unavailable

-3.30% session move Open Argus

Details

News Market Reaction – MRNS

The recorded move for MRNS in the trading session of this news was -3.30%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2^nd Annual CNS Forum.

Additional details can be found below:

Title:		A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO)
Date:		Tuesday, June 23, 2020
Time:		3:20 PM Eastern Time
Format:		Fireside chat

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus.
           
CONTACT: 
Sasha Damouni Ellis
Vice President, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Marinus Pharmaceuticals present at the CNS Forum?

Marinus Pharmaceuticals will present at the CNS Forum on June 23, 2020, at 3:20 PM Eastern Time.

What is the focus of Marinus Pharmaceuticals' presentation at the CNS Forum?

The focus of the presentation will be a pipeline update related to their therapeutics for rare seizure disorders.

Who will speak during the Marinus Pharmaceuticals presentation at the CNS Forum?

CEO Scott Braunstein and CMO Joe Hulihan will speak during the presentation.

What is Ganaxolone and its significance for Marinus Pharmaceuticals?

Ganaxolone is a drug developed by Marinus that modulates GABAA receptors and aims to treat various seizure disorders.

What clinical trials is Marinus Pharmaceuticals currently undertaking?

Marinus is conducting a Phase 3 trial for CDKL5 deficiency disorder and several other trials for different seizure-related conditions.